ASCO 2023 | Novel immunotherapy approaches for MMR-proficient colorectal cancer

Jennifer Rachel Eads, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, gives an overview of how patients with mismatch-repair (MMR)-proficient colorectal cancer can be more responsive to immunotherapy. Despite MMR-proficient colorectal cancer being seen as an immunologically cold tumor, the addition of chemotherapy and targeted therapy or radiotherapy may increase the efficacy of immunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.